Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Academic Article uri icon

Overview

MeSH

  • Adenoviridae
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Time Factors
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

MeSH Major

  • Coronary Disease
  • DNA, Complementary
  • Endothelial Growth Factors
  • Gene Transfer Techniques
  • Genetic Therapy
  • Lymphokines

abstract

  • To summarize the 6-month follow-up of a cohort of patients with clinically significant coronary artery disease who received direct myocardial injection of an E1-E3- adenovirus (Ad) gene transfer vector (Ad(GV)VEGF121.10) expressing the human vascular endothelial growth factor (VEGF) 121 cDNA to induce therapeutic angiogenesis. Therapeutic angiogenesis describes a novel approach to the treatment of vascular occlusive disease that uses the administration of growth factors known to induce neovascularization of ischemic tissues. Direct myocardial injection of Ad(GV)VEGF121.10 into an area of reversible ischemia was carried out in 21 patients as an adjunct to conventional coronary artery bypass grafting (group A, n = 15) or as sole therapy using a minithoracotomy (group B, n = 6). No evidence of systemic or cardiac-related adverse events related to vector administration was observed up to 6 months after therapy. Trends toward improvement in angina class and exercise treadmill testing at 6-month follow-up in the sole therapy group suggest the effects of this therapy are persistent for > or =6 months. This study suggests that direct myocardial administration of Ad(GV)VEGF121.10 appears to be well tolerated in patients with clinically significant coronary artery disease. Initiation of phase II evaluation of this therapy appears warranted.

publication date

  • October 1999

has subject area

  • Adenoviridae
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Coronary Disease
  • DNA, Complementary
  • Endothelial Growth Factors
  • Female
  • Gene Transfer Techniques
  • Genetic Therapy
  • Humans
  • Lymphokines
  • Male
  • Middle Aged
  • Time Factors
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Research

keywords

  • Clinical Trial
  • Clinical Trial, Phase I
  • Journal Article

Identity

Language

  • eng

PubMed Central ID

  • PMC1420895

PubMed ID

  • 10522716

Additional Document Info

start page

  • 466

end page

  • 70; discussion 470-2

volume

  • 230

number

  • 4